S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:ADGI

Adagio Therapeutics (ADGI) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$3.40
▼
$4.78
52-Week Range
N/A
Volume
22,357 shs
Average Volume
2.27 million shs
Market Capitalization
$504.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

ADGI stock logo

About Adagio Therapeutics (NASDAQ:ADGI) Stock

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.


ADGI Stock News Headlines

August 11, 2023 | msn.com
Adagio Therapeutics GAAP EPS of -$0.46 misses by $0.11
April 3, 2023 | benzinga.com
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
March 30, 2023 | markets.businessinsider.com
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses to Contact the Firm
March 3, 2023 | benzinga.com
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Invivyd, Inc. – IVVD, ADGI
February 9, 2023 | benzinga.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. - IVVD; ADGI
January 25, 2023 | finance.yahoo.com
Form 8.3 - Horizon Therapeutics Plc
December 19, 2022 | benzinga.com
Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
October 17, 2022 | bizjournals.com
Adagio Therapeutics, now Invivyd, retools its strategy after losing two executives
September 15, 2022 | finanznachrichten.de
Adagio Therapeutics, Inc.: Adagio Therapeutics Announces Corporate Name Change to Invivyd
September 12, 2022 | tmcnet.com
Invivyd Announces Multiple Next Generation COVID-19 Antibody
September 12, 2022 | finance.yahoo.com
Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants
August 22, 2022 | 247wallst.com
Hedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake to 8.5%
August 17, 2022 | seekingalpha.com
Adagio Therapeutics GAAP EPS of -$0.47
August 15, 2022 | finance.yahoo.com
Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
July 6, 2022 | finance.yahoo.com
Is Adagio Therapeutics (NASDAQ:ADGI) In A Good Position To Invest In Growth?
July 5, 2022 | nasdaq.com
Adagio Elevates Interim Chief Executive David Hering To Permanent CEO
July 5, 2022 | finance.yahoo.com
Mithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy Campaign
July 5, 2022 | finance.yahoo.com
Adagio Announces David Hering Named Permanent Chief Executive Officer and Director
July 2, 2022 | benzinga.com
(ADGI) News: Did You Lose Money on Your Adagio Therapeutics Investment? Stock Price has Plummeted Since IPO - Contact Johnson Fistel
May 13, 2022 | investing.com
Adagio Therapeutics Reports Q1 Net Loss of $100.7M, Cash Position of $532.2M
May 13, 2022 | finance.yahoo.com
Adagio Therapeutics Reports First Quarter 2022 Financial Results
April 14, 2022 | seekingalpha.com
Adagio stock falls after pausing filing plans for COVID therapy with FDA
April 14, 2022 | finance.yahoo.com
Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request
April 7, 2022 | finance.yahoo.com
When Will Adagio Therapeutics, Inc. (NASDAQ:ADGI) Breakeven?
March 31, 2022 | bizjournals.com
The Petri Dish: Adagio says its antibody works against omicron now
See More Headlines
Receive ADGI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADGI Company Calendar

Last Earnings
11/14/2021
Today
9/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADGI
CUSIP
N/A
CIK
1832038
Web
adagiotx.com
Phone
603-252-2274
Fax
N/A
Employees
2,021
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.15)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-226,790,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-57.14%
Return on Assets
-50.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.09
Quick Ratio
7.09

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.02 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
108,831,000
Free Float
N/A
Market Cap
$504.98 million
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. David Hering M.B.A. (Age 46)
    CEO & Director
    Comp: $453.76k
  • Ms. Jill Andersen J.D. (Age 49)
    Chief Legal Officer & Corp. Sec.
    Comp: $580.12k
  • Ms. Laura Walker Ph.D. (Age 37)
    Co-Founder & Chief Scientific Officer
  • Ms. Jane Pritchett V. Henderson (Age 56)
    CFO, Chief Bus. Officer & Treasurer
  • Dr. Rebecca Dabora Ph.D. (Age 62)
    Chief Technology & Manufacturing Officer
  • Dr. Elham Hershberger Pharm.D. (Age 54)
    Chief Devel. Officer
  • Mr. Eric W. Kimble M.B.A. (Age 54)
    Chief Commercial Officer
  • Mr. Ed Campanaro
    Sr. VP of Clinical Operations

Key Competitors

View All Competitors













ADGI Stock - Frequently Asked Questions

How were Adagio Therapeutics' earnings last quarter?

Adagio Therapeutics, Inc. (NASDAQ:ADGI) announced its quarterly earnings data on Sunday, November, 14th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.24.

When did Adagio Therapeutics IPO?

(ADGI) raised $301 million in an IPO on Friday, August 6th 2021. The company issued 17,700,000 shares at a price of $16.00-$18.00 per share.

What is Adagio Therapeutics' stock symbol?

Adagio Therapeutics trades on the NASDAQ under the ticker symbol "ADGI."

How much money does Adagio Therapeutics make?

Adagio Therapeutics (NASDAQ:ADGI) has a market capitalization of $0.00. The company earns $-226,790,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis.

How many employees does Adagio Therapeutics have?

The company employs 2,021 workers across the globe.

How can I contact Adagio Therapeutics?

The official website for the company is adagiotx.com. The company can be reached via phone at 603-252-2274 or via email at monique@thrustsc.com.

This page (NASDAQ:ADGI) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -